Rodriguez-Gonzalez, 1,208 patient HCQ late treatment study: 23% lower mortality [p=0.26] https://c19p.org/rodriguezgonzalez
copied to clipboard
COVID-19 in hospitalized patients in Spain: a cohort study in Madrid
et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106249
Retrospective 1255 patients in Spain showing lower mortality with HCQ. Subject to confounding by indication.
|
risk of death, 22.8% lower, RR 0.77, p = 0.26, treatment 251 of 1,148 (21.9%), control 17 of 60 (28.3%), NNT 15.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Rodriguez-Gonzalez et al., 11/28/2020, retrospective, Spain, Europe, peer-reviewed, 20 authors, average treatment delay 6.0 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.